Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)
Sponsor: NeuroBo Pharmaceuticals Inc.
Listed as NCT06054815, this PHASE2 trial focuses on NON-ALCOHOLIC STEATOHEPATITIS and remains completed. Sponsored by NeuroBo Pharmaceuticals Inc., it has been updated 11 times since 2023, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NeuroBo Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .